Respimat - PDFSEARCH.IO - Document Search Engine

Respimat
Results: 48

#	Item
21	Amendment to NDA[removed], S-029 Add to Reading List Source URL: www.fda.gov Language: English Pharmacology Clinical research Epoxides Pfizer Tiotropium bromide Chronic obstructive pulmonary disease Acute exacerbation of chronic obstructive pulmonary disease Placebo Respimat Medicine Health Pulmonology
22	OLODATEROL RESPIMAT Boehringer Ingelheim NDA[removed]FDA Advisory Committee Briefing Document December 19, 2012 Add to Reading List Source URL: www.fda.gov Language: English Chemistry Chronic lower respiratory diseases Respiratory physiology Pulmonary function testing Spirometry Obstructive lung disease Phenols Indacaterol Respimat Pulmonology Medicine Respiratory therapy
23	SPIRIVA HandiHaler (tiotropium bromide inhalation powder) NDA # [removed]s029 Add to Reading List Source URL: www.fda.gov Language: English Chronic lower respiratory diseases Smoking Muscarinic antagonists Thiophenes Epoxides Tiotropium bromide Respimat Chronic obstructive pulmonary disease Acute exacerbation of chronic obstructive pulmonary disease Medicine Health Pulmonology
24	PULMONARY ALLERGY DRUGS ADVISORY COMMITTEE MEETING February 23, 2012 FDA White Oak Campus, The Great Room White Oak Conference Center Silver Spring, Maryland Add to Reading List Source URL: www.fda.gov Language: English Health Bronchodilators Muscarinic antagonists Design of experiments Pharmaceutical industry Tiotropium bromide Chronic obstructive pulmonary disease Clinical trial Respimat Medicine Chemistry Clinical research
25	PULMONARY-ALLERGY DRUGS ADVISORY COMMITTEE MEETING January 29, 2013 NDA[removed]: olodaterol (proposed trade name Striverdi Respimat) for the proposed indication of long-term, once-daily maintenance bronchodilator treatmen Add to Reading List Source URL: www.fda.gov Language: English Phenols Respiratory therapy Combination drugs Alcohols Asthma Formoterol Salmeterol Obstructive lung disease Indacaterol Medicine Pulmonology Pharmacology
26	CI-1 Striverdi® Respimat® (olodaterol) Inhalation Spray United States Food and Drug Administration Pulmonary-Allergy Drugs Advisory Committee Add to Reading List Source URL: www.fda.gov Language: English Health Chronic lower respiratory diseases Smoking Pulmonary function testing Respiratory physiology Chronic obstructive pulmonary disease Respimat Inhaler Asthma Pulmonology Medicine Respiratory therapy
27	DOC Document Add to Reading List Source URL: ozone.unep.org Language: English - Date: 2011-03-18 07:15:02 Dosage forms Respiratory therapy Refrigerants Asthma Phenols Inhaler Respimat Dry powder inhaler Metered-dose inhaler Medicine Chemistry Pharmacology
28	US Food and Drug Administration Meeting of the Pulmonary-Allergy Drugs Advisory Committee November 19, 2009 Badrul A. Chowdhury, MD, PhD Add to Reading List Source URL: www.fda.gov Language: English Bronchodilators Epoxides Thiophenes Tiotropium bromide Respimat Chronic obstructive pulmonary disease Acute exacerbation of chronic obstructive pulmonary disease Stroke Aging-associated diseases Medicine Health
29	Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes vs mono-components in COPD in two 1-year studies[removed]Roland Buhl Add to Reading List Source URL: www.boehringer-ingelheim.com Language: English - Date: 2014-09-07 02:29:07 Pulmonary function testing Respiratory physiology Muscarinic antagonists Thiophenes Tiotropium bromide Spirometry Chronic obstructive pulmonary disease Bronchodilator Pulmonology Medicine Respiratory therapy
30	Once-daily tiotropium Respimat® add-on to ICS ± LABA improves control across asthma severities[removed]Tiotropium Respimat® for use in asthma is currently being reviewed by regulatory Add to Reading List Source URL: www.boehringer-ingelheim.com Language: English - Date: 2014-09-07 00:03:40 Asthma Respiratory therapy Chronic lower respiratory diseases Bioethics Pharmacology Tiotropium bromide Salmeterol Placebo Chronic obstructive pulmonary disease Medicine Health Pulmonology

UPDATE